Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer announced that they've started testing the safety profile of their novel oral antiviral investigational drug candidate for SARS-CoV-2 infections.
Biosimilars: Advancing Science to Help Improve Patient Access to Medicines
Biologics are among the most powerful drugs to treat cancer and autoimmune diseases today. Made from living organisms, such as bacteria or yeast, these therapies can specifically target cells or stimulate the immune system to fight tumors or inflammation.